Minerva Neurosciences, Inc. (NERV) Investor Relations Documents

Minerva Neurosciences, Inc. (NERV) investor relations documents from the company's IR site: 11 press releases. Read in-app with summaries. First-party data.

Investor relations documents — source: company IR site

Published	Type	Document
2026-08-07	Press release	Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates
2026-06-01	Press release	Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline P
2026-05-18	Press release	Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference
2026-05-05	Press release	Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates
2026-04-02	Press release	Minerva Announces Leadership Transition
2026-03-31	Press release	Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Trea
2026-03-25	Press release	Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanza
2026-03-12	Press release	Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum
2026-03-11	Press release	Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates
2026-03-04	Press release	Minerva Neurosciences to Participate in The Citizens Life Sciences Conference
2026-01-26	Press release	Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the Fi

NERV overview · NERV earnings · NERV financials · NERV KPIs · NERV ownership · NERV peers · NERV filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.